Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 1/2020

01-01-2020 | Ultrasound | Original Article

Long-term positive psychological outcomes in an Australian pancreatic cancer screening program

Authors: R. S. O’Neill, B. Meiser, S. Emmanuel, D. B. Williams, A. Stoita

Published in: Familial Cancer | Issue 1/2020

Login to get access

Abstract

Screening for pancreatic cancer (PC) in high-risk groups aimed to detect early cancers is currently done only in the research setting, and data on psychological outcomes of screening in these populations is scarce. To determine the psychological impact of a national Australian pancreatic screening program, a prospective study was conducted using validated psychological measures: impact of events scale (IES), psychological consequences questionnaire (PCQ) and the cancer worry scale. Measures were administered at baseline, 1-month and at 1-year post-enrolment and correlations with abnormal endoscopic ultrasound (EUS) results were calculated. Over a 6-year period, 102 participants were recruited to the screening program. Thirty-nine patients (38.2%) had an abnormal endoscopic ultrasound, and two patients (2.0%) were diagnosed with PC and two with other malignancies. Those with a personal history of cancer or a positive BRCA2 mutation demonstrated significantly increased worry about developing other types of cancer at baseline (p < 0.01). Irrespective of EUS result, there was a significant decrease of total IES score at 1 year (Z = − 2.0, p = 0.041). In patients with abnormal EUS results, there was a decrease in the total IES score at 1 year (Z = − 2.5, p = 0.011). In participants deemed to be most distressed at baseline based on their negative PCQ score, there was a significant decrease of the total PCQ (Z = − 3.2, p = 0.001), emotional (Z = − 3.0, p = 0.001), social (Z = 3.0, p = 0.001) and physical (Z = − 2.8, p = 0.002) subscale at 1-year post-intervention. This study provides evidence of the long-term psychological benefits of PC screening in high-risk patients. There was no negative impact of screening in the short-term and the positive benefits appeared at 1-year post-intervention irrespective of screening result.
Appendix
Available only for authorised users
Literature
1.
2.
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74(11):2913–2921PubMedCrossRef
3.
Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, Altekruse S et al (2013) SEER cancer statistics review, 1975–2010. National Cancer Institute, Bethesda, p 12
4.
Gilbert JW, Wolpin B, Clancy T, Wang J, Mamon H, Shinagare AB et al (2017) Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification. Ann Oncol 28(9):2067–2076PubMedPubMedCentralCrossRef
5.
6.
Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJA et al (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64(7):2634–2638PubMedCrossRef
7.
Permuth-Wey J, Egan KM (2009) Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer 8(2):109–117PubMedCrossRef
8.
9.
Tersmette AC, Petersen GM, Offerhaus GJA, Falatko FC, Brune KA, Goggins M et al (2001) Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 7(3):738–744PubMed
10.
Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV et al (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119(6):1447–1453PubMedCrossRef
11.
Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley J-W, Kamel I et al (2013) International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62(3):339–347PubMedCrossRef
12.
Van Asperen C, Brohet R, Meijers-Heijboer E, Hoogerbrugge N, Verhoef S, Vasen H et al (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42(9):711–719PubMedPubMedCentralCrossRef
13.
Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N et al (2010) PALB2 mutations in European familial pancreatic cancer families. Clin Genet 78(5):490–494PubMedCrossRef
14.
Takai E, Yachida S, Shimizu K, Furuse J, Kubo E, Ohmoto A et al (2016) Germline mutations in Japanese familial pancreatic cancer patients. Oncotarget 7(45):74227–74235PubMedPubMedCentralCrossRef
15.
Schneider R, Slater EP, Sina M, Habbe N, Fendrich V, Matthai E et al (2011) German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer 10(2):323–330PubMedCrossRef
16.
Southey MC, Goldgar DE, Winqvist R, Pylkas K, Couch F, Tischkowitz M et al (2016) PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet 53(12):800–811PubMedCrossRef
17.
Lynch HT, Fusaro RM, Lynch JF, Brand R (2008) Pancreatic cancer and the FAMMM syndrome. Fam Cancer 7(1):103–112PubMedCrossRef
18.
Rebours V, Boutron-Ruault M-C, Schnee M, Férec C, Maire F, Hammel P et al (2008) Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol 103(1):111–119PubMedCrossRef
19.
Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM et al (2009) Risk of pancreatic cancer in families with Lynch syndrome. J Am Med Assoc 302(16):1790–1795CrossRef
20.
Ariyama J, Suyama M, Ogawa K, Ikari T (1986) Screening of pancreatic neoplasms and the diagnostic rate of small pancreatic neoplasms. Nihon Rinsho Jpn J Clin Med 44(8):1729–1734
21.
Lu C, Xu C-F, Wan X-Y, Zhu H-T, Yu C-H, Li Y-M (2015) Screening for pancreatic cancer in familial high-risk individuals: a systematic review. World J Gastroenterol 21(28):8678PubMedPubMedCentralCrossRef
22.
Capurso G, Signoretti M, Valente R, Arnelo U, Lohr M, Poley JW et al (2015) Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals. World J Gastrointest Endosc 7(9):833–842PubMedPubMedCentralCrossRef
23.
Toft J, Hadden WJ, Laurence JM, Lam V, Yuen L, Janssen A et al (2017) Imaging modalities in the diagnosis of pancreatic adenocarcinoma: a systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy. Eur J Radiol 92:17–23PubMedCrossRef
24.
Raut C, Grau AM, Staerkel GA, Kaw M, Tamm EP, Wolff RA, Vauthey JN, Lee JE, Pisters PW, Evans DB (2003) Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J Gastrointest Surg 7:118–126PubMedCrossRef
25.
Breitkopf CR, Sinicrope PS, Rabe KG, Brockman TA, Patten CA, McWilliams RR et al (2012) Factors influencing receptivity to future screening options for pancreatic cancer in those with and without pancreatic cancer family history. Hered Cancer Clin Pract 10(1):8PubMedPubMedCentralCrossRef
26.
Horowitz M, Wilner N, Alvarez W (1979) Impact of event scale: a measure of subjective stress. Psychosom Med 41(3):209–218PubMedCrossRef
27.
Zilberg NJ, Weiss DS, Horowitz MJ (1982) Impact of event scale: a cross-validation study and some empirical evidence supporting a conceptual model of stress response syndromes. J Consult Clin Psychol 50(3):407PubMedCrossRef
28.
Cella DF, Mahon SM, Donovan MI (1990) Cancer recurrence as a traumatic event. Behav Med 16(1):15–22PubMedCrossRef
29.
Cockburn J, De Luise T, Hurley S, Clover K (1992) Development and validation of the PCQ: a questionnaire to measure the psychological consequences of screening mammography. Soc Sci Med 34(10):1129–1134PubMedCrossRef
30.
Lerman C, Trock B, Rimer BK, Jepson C, Brody D, Boyce A (1991) Psychological side effects of breast cancer screening. Health Psychol 10(4):259PubMedCrossRef
31.
Paiella S, Capurso G, Cavestro GM, Butturini G, Pezzilli R, Salvia R et al (2019) Results of first-round of surveillance in individuals at high-risk of pancreatic cancer from the AISP (Italian Association for the Study of the Pancreas) registry. Am J Gastroenterol 114(4):665–670PubMedCrossRef
32.
Signoretti M, Bruno MJ, Zerboni G, Poley J-W, Delle Fave G, Capurso G (2018) Results of surveillance in individuals at high-risk of pancreatic cancer: a systematic review and meta-analysis. United Eur Gastroenterol J 6(4):489–499CrossRef
33.
Konings IC, Harinck F, Kuenen MA, Sidharta GN, Kieffer JM, Aalfs CM et al (2017) Factors associated with cancer worries in individuals participating in annual pancreatic cancer surveillance. Fam Cancer 16(1):143–151PubMedCrossRef
34.
Douma KF, Aaronson NK, Vasen HF, Gerritsma MA, Gundy CM, Janssen EP et al (2010) Psychological distress and use of psychosocial support in familial adenomatous polyposis. Psycho-Oncology 19(3):289–298PubMedCrossRef
35.
Franke FS, Matthäi E, Slater EP, Schicker C, Kruse J, Bartsch DK (2018) German National Case Collection for familial pancreatic Cancer (FaPaCa)-acceptance and psychological aspects of a pancreatic cancer screening program. Hered Cancer Clin Pract 16(1):17PubMedPubMedCentralCrossRef
36.
Maheu C, Vodermaier A, Rothenmund H, Gallinger S, Ardiles P, Semotiuk K et al (2010) Pancreatic cancer risk counselling and screening: impact on perceived risk and psychological functioning. Fam Cancer 9(4):617–624PubMedCrossRef
37.
Konings IC, Sidharta GN, Harinck F, Aalfs CM, Poley JW, Kieffer JM et al (2016) Repeated participation in pancreatic cancer surveillance by high-risk individuals imposes low psychological burden. Psycho-Oncology 25(8):971–978PubMedCrossRef
38.
Cazacu IM, Chavez AAL, Saftoiu A, Bhutani MS (2019) Psychological impact of pancreatic cancer screening by EUS or magnetic resonance imaging in high-risk individuals: a systematic review. Endosc Ultrasound 8(1):17PubMedCrossRef
39.
Mckay S, Gunasingam N, Meiser B, Williams DB, Stoita A (2017) Pancreatic cancer screening in high risk individuals does not have negative psychological impact in the short or long term. Gastroenterology 152(5):S277CrossRef
40.
Hart SL, Torbit LA, Crangle CJ, Esplen MJ, Holter S, Semotiuk K et al (2012) Moderators of cancer-related distress and worry after a pancreatic cancer genetic counseling and screening intervention. Psycho-Oncology. 21(12):1324–1330PubMedCrossRef
41.
42.
Brett J, Bankhead C, Henderson B, Watson E, Austoker J (2005) The psychological impact of mammographic screening. A systematic review. Psychooncology 14(11):917–938PubMedCrossRef
43.
Brain KE, Lifford KJ, Fraser L, Rosenthal AN, Rogers MT, Lancastle D et al (2012) Psychological outcomes of familial ovarian cancer screening: no evidence of long-term harm. Gynecol Oncol 127(3):556–563PubMedCrossRef
44.
Cantor SB, Volk RJ, Cass AR, Gilani J, Spann SJ (2002) Psychological benefits of prostate cancer screening: the role of reassurance. Health Expect 5(2):104–113PubMedPubMedCentralCrossRef
45.
Kirkøen B, Berstad P, Botteri E, Åvitsland TL, Ossum AM, De Lange T et al (2016) Do no harm: no psychological harm from colorectal cancer screening. Br J Cancer 114(5):497PubMedPubMedCentralCrossRef
46.
Gopie JP, Vasen HF, Tibben A (2012) Surveillance for hereditary cancer: does the benefit outweigh the psychological burden?—a systematic review. Crit Rev Oncol/Hematol 83(3):329–340CrossRef
47.
Corral JE, Das A, Bruno MJ, Wallace MB (2019) Cost-effectiveness of pancreatic cancer surveillance in high-risk individuals: an economic analysis. Pancreas 48(4):526–536PubMedCrossRef
48.
Lewis ZK, Frost CJ, Venne VL (2009) Pancreatic cancer surveillance among high-risk populations: knowledge and intent. J Genet Counsel 18(3):229–238CrossRef
49.
Harinck F, Nagtegaal T, Kluijt I, Aalfs C, Smets E, Poley J-W et al (2011) Feasibility of a pancreatic cancer surveillance program from a psychological point of view. Genet Med 13(12):1015–1024PubMedCrossRef
50.
Canto MI, Almario JA, Schulick RD, Yeo CJ, Klein A, Blackford A et al (2018) Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. Gastroenterology 155(3):740–751PubMedCrossRef
51.
Corral JE, Mareth KF, Riegert-Johnson DL, Das A, Wallace MB (2019) Diagnostic yield from screening asymptomatic individuals at high risk for pancreatic cancer: a meta-analysis of cohort studies. Clin Gastroenterol Hepatol 17(1):41–53PubMedCrossRef
52.
53.
Al-Sukhni W, Borgida A, Rothenmund H, Holter S, Semotiuk K, Grant R et al (2012) Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg 16(4):771–783PubMedCrossRef
54.
Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z et al (2012) Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142(4):796–804PubMedCrossRef
55.
Topazian M, Enders F, Kimmey M, Brand R, Chak A, Clain J et al (2007) Interobserver agreement for EUS findings in familial pancreatic-cancer kindreds. Gastrointest Endosc 66(1):62–67PubMedCrossRef
Metadata
Title
Long-term positive psychological outcomes in an Australian pancreatic cancer screening program
Authors
R. S. O’Neill
B. Meiser
S. Emmanuel
D. B. Williams
A. Stoita
Publication date
01-01-2020
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2020
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-019-00147-3

Other articles of this Issue 1/2020

Familial Cancer 1/2020 Go to the issue

Short Communication

Clear cell chondrosarcoma in Von Hippel-Lindau disease

Abstracts

Abstracts of the 4th meeting of the European Hereditary Tumour Group, Barcelona, Spain, October 17–19th, 2019

Original Article

A unique case of two somatic APC mutations in an early onset cribriform-morular variant of papillary thyroid carcinoma and overview of the literature

Original Article

‘We don’t know for sure’: discussion of uncertainty concerning multigene panel testing during initial cancer genetic consultations

Short Communication

Neurofibromatosis type 2 discordance in monozygous twins

Original Article

Renal cell carcinoma in young FH mutation carriers: case series and review of the literature
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits